Lunasin

Nutraceutical / Anticancer Research

Also known as: Lunasin Peptide

Food-Derived Bioactive PeptidesResearch phase: Preclinical; available as supplementRegulatory: Not approved as drug. Available as dietary supplement (GRAS status). Not evaluated by FDA for disease claims.

Mechanism

Lunasin is a soy-derived peptide with proposed anticancer and cholesterol-lowering properties. It is available as a dietary supplement and is being researched for epigenetic effects.

Technical detail

Lunasin is a 43-amino acid peptide from soybean (Glycine max) with an RGD cell adhesion motif, a poly-aspartate tail, and a chromatin-binding helical region. It inhibits histone acetylation and has demonstrated anti-proliferative effects in multiple cancer cell lines by inducing apoptosis and inhibiting NF-κB. Also reduces LDL cholesterol via HMG-CoA reductase pathway modulation.

Evidence

The Effect of Soybean Lunasin on Cardiometabolic Risk Factors: A Randomized Clinical Trial.
Haddad Tabrizi S et al. (2020) — Journal of Dietary Supplements — PMID: 30955400
Triple-blind placebo-controlled crossover trial in 31 adults using 335 mg/day lunasin-enriched soy extract for 8 weeks found no significant improvements in lipids, glucose, insulin resistance, blood pressure, BMI, or waist circumference.
moderate

Build a personalized protocol with Lunasin →